Factor v leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer

Journal of the National Cancer Institute

Volumn 102, Issue 13, 2010, Pages 942-949

  Garber, Judy E ^a   Halabi, Susan ^b,c   Tolaney, Sara M ^a   Kaplan, Ellen ^c   Archer, Laura ^c   Atkins, James N ^d   Edge, Stephen ^e   Shapiro, Charles L ^g   Dressler, Lynn ⁱ   Paskett, Electra M ^h   Kimmick, Gretchen ^j   Orcutt, James ^d   Scalzo, Anthony ^k   Winer, Eric ^a   Levine, Ellis ^f   Shahab, Nasir ^l   Berliner, Nancy ^m,n  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY   (United States)

^d Southeast Cancer Control Consortium Inc CCOP   (United Kingdom)

^e Department of Surgery ^*  (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ University of North Carolina   (United States)

^j WAKE FOREST SCHOOL OF MEDICINE   (United States)

^k SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^l UNIVERSITY OF MISSOURI   (United States)

^m BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁿ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; DNA; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BLOOD CLOTTING FACTOR 5; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADJUVANT THERAPY; ADULT; ARTERY EMBOLISM; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SMOKING; THROMBOEMBOLISM; VEIN EMBOLISM; ADJUVANT CHEMOTHERAPY; AGED; BREAST TUMOR; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PREVALENCE; RISK; RISK FACTOR; STATISTICAL MODEL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; ESTROGEN RECEPTOR MODULATORS; FACTOR V; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; ODDS RATIO; PREVALENCE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SMOKING; TAMOXIFEN; THROMBOEMBOLISM;

EID: 77954730914     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq211     Document Type: Article

References (41)

1. Fricker J. End of the road for tamoxifen? Lancet Oncol. 2004;5(1):2.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
3. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652-1662.
4. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361(9354):296-300.
5. Fisher B, Dignam J, Bryant J, et al. Five versus more than fve years of tamox-ifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88(21):1529-1542.
6. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107(23) (suppl 1):I17-I21.
7. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89(22):1673-1682.
8. Dahlback B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res. 1995;77(1):1-43.
9. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369(6475):64-67.
10. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346(8983):1133-1134.
11. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330(8):517-522. (Pubitemid 24058953)
12. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117(1):19-25.
13. Spannagl M, Heinemann LA, Schramm W. Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism? Eur J Contracept Reprod Health Care. 2000;5(2):105-112.
14. Griffn JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood. 1993; 82(7):1989-1993.
15. Weitz IC, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer. 1997;79(10):2024-2027.
16. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14(10):2738-2746.
17. Rothman KJ, Greenland S. Modern Epidemiology. 2nd edn. Philadelphia, PA: Lippincott, Williams and Wilkins; 1998.
18. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352(9122):98-101.
19. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360(9336):817-824
20. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114): 1451-1467.
21. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99(4):283-290.
22. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21(4):602-606.
23. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2004;22(16):3309-3315.
24. Day R, Ganz PA, Costantino JP. Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study. J Natl Cancer Inst. 2001;93(21):1615-1623.
25. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol. 1999;17(9):2659-2669.
26. Lipton A, Harvey HA, Hamilton RW. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep. 1984;68(6):887-889.
27. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis, Blood, 1996, 88, 10, 3698-3703
28. Segal JB, Brotman DJ, Necochea AJ, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembo-lism and in family members of those with a mutation: a systematic review. JAMA. 2009;301(23):2472-2485.
29. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997;277(16):1305-1307.
30. Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess. 2006;10(11):1-110.
31. De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica. 2002;87(10):1095-1108.
32. Duggan C, Marriott K, Edwards R, Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamox-ifen to prevent breast cancer. J Clin Oncol. 2003;21(19):3588-3593.
33. Abramson N, Costantino JP, Garber JE, Berliner N, Wickerham DL, Wolmark N. Effect of factor V Leiden and prothrombin G20210-A mutations on thromboembolic risk in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J Natl Cancer Inst. 2006;98(13):904-910.
34. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after fve years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793-1802.
35. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated fndings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262-1271.
36. Kennecke H, McArthur H, Olivotto IA, et al. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen. Cancer. 2008;112(7):1437-1444.
37. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25(5):486-492.
38. Severinsen MT, Kristensen SR, Johnsen SP, Dethlefsen C, Tjonneland A, Overvad K. Smoking and venous thromboembolism: a Danish follow-up study. J Thromb Haemost. 2009;7(8):1297-1303.
39. Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol. 2007;139(2):289-296.
40. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6(6):401-410.
41. Mandala M, Curigliano G, Bucciarelli P, et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol. 2004;15(4):590-593.